Comparative Pharmacology
Head-to-head clinical analysis: CENESTIN versus DIETHYLSTILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENESTIN versus DIETHYLSTILBESTROL.
CENESTIN vs DIETHYLSTILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and exerting effects on reproductive tissues, bone, cardiovascular system, and CNS.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
0.45 mg orally once daily; titrate up to 1.25 mg once daily based on symptoms. Maximum dose 1.25 mg/day.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
None Documented
None Documented
Terminal elimination half-life is approximately 10-24 hours for conjugated estrogens; this long half-life allows for once-daily dosing and sustained estrogenic effects.
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Primarily renal, with approximately 90% excreted in urine as glucuronide and sulfate conjugates; about 10% excreted in feces via bile.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."